Mink Therapeutics Inc (INKT) Stock Analysis

Mink Therapeutics Inc (INKT) is a publicly traded company in the HEALTHCARE sector. It trades at $11.96, carries a market capitalization of $61.70M. This page summarizes the public market data, fundamentals, and frequently asked questions for INKT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Mink Therapeutics Inc currently has a Bullish sentiment score of 0.20.

About Mink Therapeutics Inc

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical firm headquartered in New York, focused on the development of innovative allogeneic invariant natural killer T-cell therapies for cancer and immune-mediated diseases. By leveraging the unique capabilities of these immune cells, MiNK is advancing a promising therapeutic pipeline designed to provide next-generation treatment options in the rapidly evolving field of cell-based immunotherapies. The company's strategic emphasis on pione...

GNG Research Analysis

GNG Research scores Mink Therapeutics Inc (INKT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for INKT.

Frequently Asked Questions

Does INKT pay dividends?

Mink Therapeutics Inc (INKT) does not currently pay a regular dividend.

What is INKT's market cap?

Mink Therapeutics Inc (INKT) has a market capitalization of $61.70M with a current stock price of $11.96.